Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed/Refractory Large B-cell Lymphoma Subjects

A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed/Refractory Large B-cell Lymphoma Subjects
Conditions:   Refractory Diffuse Large B-cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory High Grade B-Cell Lymphoma;   Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Intervention:   Drug: Tisagenlecleucel
Sponsor:   NeoImmuneTech
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 14, 2021 / by / in
Comments